ETH-LAD

What is ETH-LAD?

ETH-LAD, also known as 6-ethyl-6-nor-LSD or N6-ethylnorlysergic acid diethylamide, is a synthetic psychedelic lysergamide related to LSD. Its defining structural change is an ethyl group at the N6 position, replacing the methyl group found in LSD. ETH-LAD is therefore part of the N6-substituted lysergamide series that also includes AL-LAD.

Chemistry and analytical identification

ETH-LAD retains the ergoline core and diethylamide group of LSD. The N6 ethyl substitution changes the molecular structure without modifying the amide portion. Research on N6-alkyl lysergamides has shown that changing this substituent can influence receptor affinity and behavioural activity. In animal drug-discrimination studies, ETH-LAD has shown LSD-like effects, with some reports suggesting higher potency than LSD in particular models. These comparisons cannot be transferred directly to human potency.

ETH-LAD appeared on the new psychoactive substance market in blotter and powder forms. Brandt and colleagues characterized it alongside 1P-ETH-LAD using GC-MS, electrospray mass spectrometry, GC solid-state infrared analysis, HPLC diode-array detection and NMR. Their work provided reference data for forensic identification and also showed that 1P-ETH-LAD can form ETH-LAD during incubation with human serum. The study is available as “Return of the lysergamides. Part III: Analytical characterization of ETH-LAD and 1P-ETH-LAD”.

Pharmacology

ETH-LAD produces LSD-like behavioural effects in animal models and is understood to act primarily through serotonergic mechanisms, particularly 5-HT2A receptor activation. The structural relationship to LSD is close, but the ethyl group at N6 changes the interaction profile. Animal studies have reported that ETH-LAD can be more potent than LSD in some drug-discrimination paradigms, while other behavioural measures have produced different relative rankings.

Such differences are not necessarily contradictory. Receptor assays, drug-discrimination tests and the mouse head-twitch response measure different aspects of pharmacology. Their results cannot be combined into a single estimate of ETH-LAD’s potency in humans.

Subjective effects

Human descriptions of ETH-LAD come mainly from user reports, including those summarized in PsychonautWiki’s ETH-LAD entry, and an anonymous online survey that included it alongside AL-LAD and 1P-LSD. In that 2017 survey of LSD analogues, respondents described the group as psychedelic, with a modal duration of around eight hours and a peak near two hours. The study combined reports for several analogues and did not chemically confirm the substances, so it cannot provide an isolated clinical profile for ETH-LAD.

Accounts specific to ETH-LAD often emphasize intense visual effects, including geometric patterns, colour enhancement and changes in depth perception. The cognitive experience is sometimes described as more demanding or mentally immersive than AL-LAD, although this distinction is based on subjective reports rather than controlled comparison. Anxiety, confusion and physical discomfort are also described.

Physical and visual effectsCognitive and emotional effects
  • Visual enhancement: colours, edges and fine details may appear more pronounced.
  • Geometry: repeating patterns and complex visual structures are described.
  • Distortions: drifting surfaces, tracers and changes in perceived depth may occur.
  • Stimulation: increased energy and wakefulness are reported.
  • Discomfort: nausea, muscle tension and restlessness may accompany the experience.
  • Introspection: attention may turn toward abstract ideas and personal memories.
  • Thought acceleration: associations can become rapid and difficult to follow.
  • Emotional changes: euphoria and increased appreciation of music are reported, alongside anxiety or confusion.
  • Time distortion: the passage of time may seem altered.

Metabolism and interpretation

ETH-LAD is also relevant to the interpretation of 1P-ETH-LAD exposure. In an in-vitro human serum experiment, 1P-ETH-LAD was converted to ETH-LAD, although the parent compound remained detectable after 24 hours. This supports a possible prodrug relationship for 1P-ETH-LAD; it does not establish that ETH-LAD itself is converted to another lysergamide or that its metabolism is identical to LSD.

Although ETH-LAD has a longer research history than many newer lysergamides, modern human pharmacokinetic studies remain limited. Its analytical identity and animal pharmacology are better characterized than its clinical effects or long-term safety.

ETH-LAD Products

ETH-LAD pellets

ETH-LAD pellets

Price range: $473.00 through $2,930.00
Select options
ETH-LAD blotters

ETH-LAD blotters

Price range: $420.00 through $2,100.00
Select options
ETH-LAD liquid

ETH-LAD liquid

Price range: $410.00 through $2,882.00
Select options

Scientific Data

Identity and Structure

Chemical NameETH-LAD
Catalog Entity TypeCompound
FormulaC21H27N3O
Molar Mass337.467 g·mol−1
CAS65527-62-0
CAS Numbers and Substance Forms65527-62-0
SynonymsETH-LAD; ETHLAD; 6-Ethyl-6-nor-lysergic acid diethylamide; 6-Ethyl-6-nor-LSD; N(6)-Ethyl-nor-LSD; 9,10-Didehydro-N,N,6-triethylergoline-8β-carboxamide
IUPAC Name(6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9- hexahydroindolo-[4,3-fg]quinoline-9-carboxamide
InChIInChI=1S/C21H27N3O/c1-4-23(5-2)21(25)15-10-17-16-8-7-9-18-20(16)14(12-22-18)11-19(17)24(6-3)13-15/h7-10,12,15,19,22H,4-6,11,13H2,1-3H3/t15-,19-/m1/s1
InChIKeyMYNOUXJLOHVSMQ-DNVCBOLYSA-N
SMILESCCN(C([C@@H]1C=C2C3=CC=CC4=C3C(C[C@H]2N(CC)C1)=CN4)=O)CC

Chemical Identifiers

PubChem CID44457783
ChemSpider ID21106300
UNII21Z2736X9Q
ChEMBL IDChEMBL22694
CompTox DTXSIDDTXSID90215823

Clinical Data

Drug ClassSerotonin receptor agonist; Serotonergic psychedelic; Hallucinogen
Routes of AdministrationOral

Pharmacokinetics

Onset of Action15 minutes–1 hour
Duration of Action8–12 hours

Legal Status

Legal Status (Wikipedia Source Text)DE: NpSG (Industrial and scientific use only)
UK: Class A
Illegal in France

Sources and Attribution

Wikipedia Source URLhttps://en.wikipedia.org/?curid=5837072